You Get A Dilution! You Get A Dilution! What About CRISPR Therapeutics? – Seeking Alpha
Seeking Alpha |
You Get A Dilution! You Get A Dilution! What About CRISPR Therapeutics?
Seeking Alpha The recent secondary offerings from Intellia Therapeutics (NTLA) and Editas Medicine (EDIT) in the CRISPR-Cas9 gene editing space beg the question – what about the final leg of the trio, CRISPR Therapeutics (CRSP)? Herein we look to calm nerves … Abingworth LLP Has $35.14 Million Holdings in Crispr Therapeutics AG (CRSP) The Brokerages Set Intellia Therapeutics Inc (NTLA) PT at $29.00 |
